Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, ITUS Capital. This analysis is provided for institutional research purposes only and is not investment advice.
"ITUS Capital posted a CY25 return of 2.4%, trailing the Nifty 50 due to an early-year drawdown in pharma, but remains constructive on long-term Indian equities due to superior portfolio-level growth and margins."
In this update for the period ending June 2025, ITUS Capital highlights the fund's long-term performance and strategic responses to recent market challenges. Since its inception in January 2017, the fund has delivered an annualized return of 18.72%, outperforming its benchmark, the Nifty 50, which returned 15.73% IRR. However, during CY25, the portfolio grew by 2.4%, lagging the benchmark by 6%. This underperformance was primarily driven by a 13.8% drawdown in the year's first two months, heavily impacted by the portfolio's pharmaceutical holdings. Despite this, the fund has staged a healthy recovery and expects to sustain its outperformance due to stronger growth (16.3% YoY TTM revenue growth) and superior margins (31.5% EBITDA margins) relative to the Nifty 500 index. The manager observes a narrowing of corporate earnings growth across India and notes a 4.8% downward revision in FY26 analyst estimates. ITUS remains constructive on Indian equities due to robust domestic flows and a recent resurgence in foreign portfolio investments. Strategically, the fund is focusing on high-quality market leaders, expanding exposures to Chemicals and Building Materials (Cement), while maintaining core allocations in Banks, Healthcare, and FMCG.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: ITUS Capital posted a CY25 return of 2.4%, trailing the Nifty 50 due to an early-year drawdown in pharma, but remains constructive on long-term Indian equities due to superior port...
Growth Outlook
Market outlook remains high conviction: ITUS Capital posted a CY25 return of 2.4%, trailing the Nifty 50 due to an early-year drawdown in pharma, but remains constructive on long-term Indian equities due to superior port...
Risk Appetite
Risk appetite posture is high conviction: ITUS Capital posted a CY25 return of 2.4%, trailing the Nifty 50 due to an early-year drawdown in pharma, but remains constructive on long-term Indian equities due to superior port...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. ITUS Capital posted a CY25 return of 2.4%, trailing the Nifty 50 due to an early-year drawdown in pharma, but remains constructive on long-term Indian equities due to superior port...
Forward Guidance
Forward guidance signal: ITUS Capital posted a CY25 return of 2.4%, trailing the Nifty 50 due to an early-year drawdown in pharma, but remains constructive on long-term Indian equities due to superior port...
Language Signal
Tone analysis indicates high conviction language: ITUS Capital posted a CY25 return of 2.4%, trailing the Nifty 50 due to an early-year drawdown in pharma, but remains constructive on long-term Indian equities due to superior port...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. ITUS Capital posted a CY25 return of 2.4%, trailing the Nifty 50 due to an early-year drawdown in pharma, but remains constructive on long-term Indian equities due to superior port...
Opportunity Density
Opportunity density index indicates high conviction actionable entry points. ITUS Capital posted a CY25 return of 2.4%, trailing the Nifty 50 due to an early-year drawdown in pharma, but remains constructive on long-term Indian equities due to superior port...
Time Horizon
Investment time horizon reflects a high conviction orientation. ITUS Capital posted a CY25 return of 2.4%, trailing the Nifty 50 due to an early-year drawdown in pharma, but remains constructive on long-term Indian equities due to superior port...
